GlassScriptPhysician profile
Jacquelyn A Johnston
NPI 1316385271
$2,448.49
in general payments reported to CMS, 2019-2025
27 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $786 · 2023: $516 · 2024: $321 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.72 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $232.87 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $231.37 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $202.18 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196.03 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $179.79 | 2021-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $114.10 | 2022-2024 | Qelbree, Qelbree |
| Alkermes, INC. | $101.87 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $89.00 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $73.85 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $69.54 | 2022-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $64.88 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $53.88 | 2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $51.47 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.96 | 2021-2025 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $37.86 | 2023-2024 | Quviviq |
| Biogen, INC. | $32.39 | 2024-2025 | Zurzuvae |
| Neurocrine Biosciences, INC. | $31.29 | 2024-2025 | Ingrezza |
| Tris Pharma INC | $28.77 | 2024-2025 | Dyanavel Xr |
| Viiv Healthcare Company | $27.63 | 2023 | Apretude |
| Sunovion Pharmaceuticals INC. | $21.84 | 2021 | |
| Neos Therapeutics, LP | $20.79 | 2022 | |
| Noven Therapeutics, LLC | $17.12 | 2024 | Xelstrym, Secuado |
| Adlon Therapeutics L.P. | $14.03 | 2021 | |
| Almatica Pharma LLC | $13.80 | 2021 | |
| Mdd US Operations, LLC | $13.49 | 2025 | Qelbree |
| Eisai INC. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.